Artikel
Effects of fucoidan extracts, derived from different Fucus species on human mesenchymal stem cells and impact on bone health and vascularization
Suche in Medline nach
Autoren
-
Fanlu Wang
- Experimental Trauma Surgery, Department of Orthopedics and Trauma Surgery, University Medical Center Schleswig-Holstein, Kiel, Germany
-
Yuejun Xiao
- Experimental Trauma Surgery, Department of Orthopedics and Trauma Surgery, University Medical Center Schleswig-Holstein, Kiel, Germany
-
Signe Helle Ptak
- Chemical Engineering, Southern Denmark University, Odense, Denmark
-
Junyu Xiong
- Experimental Trauma Surgery, Department of Orthopedics and Trauma Surgery, University Medical Center Schleswig-Holstein, Kiel, Germany
-
Julia Ohmes
- Experimental Trauma Surgery, Department of Orthopedics and Trauma Surgery, University Medical Center Schleswig-Holstein, Kiel, Germany
-
Andreas Seekamp
- Experimental Trauma Surgery, Department of Orthopedics and Trauma Surgery, University Medical Center Schleswig-Holstein, Kiel, Germany
-
Xavier Fretté
- Chemical Engineering, Southern Denmark University, Odense, Denmark
-
Sabine Fuchs
- Experimental Trauma Surgery, Department of Orthopedics and Trauma Surgery, University Medical Center Schleswig-Holstein, Kiel, Germany
| Veröffentlicht: | 7. Oktober 2020 |
|---|
Gliederung
Text
Fucoidan, the sulfated polysaccharides extracted from brown algae, has drawn growing interest in bone health applications due to its bio-functions in modulating bone formation and vascularization processes. The bioactivity of fucoidan is highly associated with chemical structures of the extracts, which vary with algae species and extraction. Thus, in-depth evaluation in terms of endotoxin content, cytotoxicity and their detailed molecular biological impact on the individual cell type in bone is needed. In this study, we compared fucoidan extracts from 3 different Fucus species including Fucus vesiculosus (FV), Fucus serratus (FS) and Fucus evanescence (FE) for their effects on human outgrowth endothelial cells (OEC) and mesenchymal stem cells (MSC).
These fucoidan extracts were firstly evaluated for endotoxin content, then cytotoxicity of each cell type was determined. The biological effects of fucoidan extracts on endothelial activation were examined by PCR and ELISA to select extracts with a low inflammatory potential. Endothelial barrier and MSC proliferation were evaluated by electric impedance measurement (ECIS). In addition, DNA assessment was used to assess effects on MSC proliferation and normalize secretory proteins to the cell number. The impact of the extracts on molecules driving vascularization was evaluated by PCR and ELISA. Finally, we investigated the effects on the osteogenic differentiation of MSC.
The results showed the endotoxin content of all extracts was ≤0.0778 EU/mL. Although OEC tolerated concentration of all extracts up to 200 µg/mL, reactions in the inflammatory response differed. MSC only tolerated lower doses and showed reduced proliferation as indicated by MTS, DNA and ECIS data. Besides FE, all extracts reduced VEGF levels, but FS showed the lowest cytotoxicity for both cell types and lowest inflammatory activation and did not interfere with differentiation of MSC. These data will be used to select those extracts with the highest biological safety and activity for further testing in more complex bone repair models in vitro and in vivo.
